Dear Members,
Thyrocare Technologies Limited
Your Directors are pleased to present their 26th Annual Report on the
business and operations together with the Audited Financial Statements (Standalone and
Consolidated) of the Thyrocare Technologies Limited
("Thyrocare"/"Company") for the financial year ended March. 31, 2026.
FINANCIAL PERFORMANCE
The summary of the Company's Audited financial performance, both
standalone and consolidated, for the financial year ended March. 31, 2026, is summarised
below:
| Particulars |
Standalone |
Consolidated |
|
2025-26 |
2024-25 |
2025-26 |
2024-25 |
| Revenue from operations |
774.27 |
633.10 |
829.04 |
687.35 |
| Other income |
13.39 |
13.34 |
16.99 |
14.83 |
| Total income |
787.66 |
646.44 |
846.03 |
702.18 |
| Expenses |
|
|
|
|
| Cost of materials consumed |
208.37 |
177.28 |
218.71 |
188.27 |
| Purchases of stock-in-trade |
1.09 |
2.00 |
1.09 |
2.00 |
| Changes in inventories of stock-in-trade |
(0.23) |
0.81 |
(0.23) |
0.81 |
| Employee benefits expense |
128.29 |
118.56 |
138.06 |
126.77 |
| Finance costs |
2.18 |
2.63 |
2.80 |
3.05 |
| Depreciation and amortisation expenses |
51.17 |
46.52 |
58.58 |
55.26 |
| Other expenses |
180.42 |
147.43 |
209.37 |
179.14 |
| Total expenses |
571.29 |
495.23 |
628.38 |
555.30 |
| Profit before share of profit of associate, exceptional items
and tax |
216.37 |
151.22 |
217.65 |
146.88 |
| Exceptional item |
(5.97) |
- |
(6.16) |
- |
| Share of Profit / (Loss) of associate and joint venture |
- |
- |
1.39 |
(1.44) |
| Profit before tax |
210.40 |
151.22 |
212.88 |
145.45 |
| Less: Current tax |
57.29 |
47.77 |
57.29 |
47.82 |
| Less: Deferred tax |
4.30 |
7.66 |
(7.26) |
6.87 |
| Profit after tax |
148.81 |
95.78 |
162.85 |
90.75 |
| Other comprehensive income for the year, net of income tax |
0.22 |
(0.73) |
0.38 |
(0.77) |
| Total comprehensive income for the year |
149.03 |
95.05 |
163.23 |
89.98 |
| Earnings per share [Nominal value of RS. 10 each] |
|
|
|
|
| (a) Basic earnings per share (INR) |
9.36 |
5.98 |
10.27 |
5.70 |
| (b) Diluted earnings per share (INR) |
9.34 |
5.96 |
10.24 |
5.69 |
On a standalone basis, the Company recorded a Revenue from Operations
of RS. 774.27/- crores, during the financial year 2025-26 as compared to RS. 633.10/-
crores in the previous financial year. The net profit after tax during the financial year
2025-26 was RS. 148.81/-crores as compared to a net profit after tax of RS. 95.78/- crores
in the previous financial year.
On a consolidated basis, the Company recorded a Revenue from Operations
of RS. 829.04/-crores, during the financial year 2025-26, as compared to RS. 687.35/-
crores in the previous financial year. The Net Profit After Tax during the
financial year 2025-26 is RS. 162.85 /- crores as compared to RS.
90.75/- crores in the previous financial year. A detailed analysis of the performance,
consolidated as well as standalone, is included in the Management Discussion and Analysis
Report, which form part of the Annual Report.
Pursuant to Section 129(3) of the Companies Act, 2013, (the
"Act") the Financial Statements of the Company, are prepared in accordance with
the relevant Indian Accounting Standards ("Ind AS") notified under Section 133
of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014, forms part of the
Annual Report.
OVERVIEW
Thyrocare is one of India's leading IT-enabled, fully automated
diagnostic laboratory service providers, delivering trusted healthcare diagnostics since
1996.
Headquartered in Navi Mumbai, the Company operates a robust network of
40 NABL-accredited laboratories across India, comprising 2 Central Processing Labs (CPLs),
21 Regional Processing Labs (RPLs), 2 Zonal Processing Labs (ZPLs), 6 Satellite Processing
Labs (SPLs), 5 Hybrid Labs and 4 Acquired Labs, with an additional International
Laboratory in Tanzania operated through its subsidiary Thyrocare Laboratories (Tanzania)
Limited.
The Company's trusted brandsAarogyam (preventive health), Jaanch
(doctor-curated diagnostics), and Her Check (women's wellness)underscore its
commitment to quality, accessibility, and affordability. Thyrocare continues to maintain
industry-leading turnaround times, with an average Absolute Turnaround Time (ATAT)
standing at 3.4 hours from sample receipt to report generation at the laboratory.
With a strong focus on innovation, inclusivity, and operational
excellence, Thyrocare remains at the forefront of transforming preventive and diagnostic
healthcare in India.
The equity shares of the Company are listed on the National Stock
Exchange of India Limited and BSE Limited.
ACHIEVEMENTS AND KEY INITIATIVES TAKEN BY THE COMPANY
During the financial year 2025-26, the Company achieved several
significant milestones and implemented key initiatives.
The milestones include:
1. We were recognized at the 4th National Diagnostics Forum &
Awards by Voice of Healthcare with two prestigious awards "Best Diagnostic Lab
Chain of the Year - National" and "Patient-Centric Diagnostic Company of the
Year - National" on January 21, 2026.
2. Thyrocare was certified as a "Great Place To Work" in
August 2025, a recognition on workplace culture, reflecting our commitment to fostering a
positive, inclusive and empowering environment for our people.
3. Onboarded Madhuri Dixit as the brand ambassador for Thyrocare, which
was an important step in strengthening brand recall and consumer trust at a national
level.
4. Expanded our footprint further with the opening of a total 7 new
labs across India this year, strengthening our Pan-India presence.
5. Expanded our specialized diagnostics portfolio significantly. One
key addition was our Allergy testing platform, where we introduced testing using the
Phadia platform. Today, our allergy portfolio has 250+SKUs, making it one of the most
comprehensive offerings in the market.
DIVIDEND
The Board of Directors ("the Board"), at its meeting held on
May 7, 2026, has recommended a final dividend of RS. 7.00/- (Rupees Seven only) per fully
paid-up equity share having face value of Rs. 10/- (Rupees Ten only) each for the
financial year 2025- 26, subject to the approval of the shareholders at the ensuing Annual
General Meeting ("AGM") of the Company.
The Company has already paid an interim dividend of RS. 7.00/- (Rupees
Seven only) per equity share (pre-bonus issue; equivalent to RS. 2.33 per share post bonus
adjustment) on equity shares of face value RS. 10 (Rupees Ten only) each for the financial
year 2025-26. Accordingly, the total dividend for the financial year ended March. 31,
2026, would aggregate to RS. 9.33 per equity share (post bonus adjustment) on equity
shares of face value RS. 10 (Rupees Ten only) each, subject to approval of the final
dividend by the shareholders.
During the previous financial year 2024-25 Company has paid the final
dividend of RS. 21.00/- (Rupees Twenty One only) per equity share having face value of Rs.
10/- (Rupees Ten only) each.
The final dividend, if approved by the shareholders at the ensuing
Annual General Meeting ("AGM") scheduled to be held on Tuesday, June 30, 2026,
will be paid to the equity shareholders holding shares as on Tuesday, June 23, 2026, being
the record date fixed for this purpose.
The said final dividend, if approved, will be paid on or before
Wednesday, July 29, 2026, after deduction of tax at source, as applicable.
DIVIDEND DISTRIBUTION POLICY
In compliance with the requirement of Regulation 43A of the Securities
and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015 (hereinafter referred to as "SEBI LODR Regulations"), the Company has
formulated its Dividend Distribution Policy, which is available on the Company's website
at:
https:// investor.thvrocare.com/wp-content/uploads/2026/06/
Divided-distribution-policy-1.pdf
RESERVES
During the financial year under review, the Company transferred an
amount of Rs. 196.25 crores from Retained Earnings to the General Reserve. The opening
balance of the General Reserve as at the beginning of the financial year was Rs. 9.17
crores.
Further, during the year, the Company capitalized a sum of Rs. 106.11
crores out of the amounts standing to the credit of the Capital Redemption Reserve (Rs.
0.96 Cr), Securities Premium Account (Rs. 78.09 Cr.), and General Reserve (Rs. 27.06 Cr.),
for the purpose of issuance and allotment of Bonus Equity Shares of Rs. 10 (Rupees Ten
only) each to the eligible shareholders of the Company.
Consequently, the closing balance of the General Reserve as at March.
31, 2026 was Rs. 178.36 crores.
CHANGES IN SHARE CAPITAL OF THE COMPANY
The Authorised Share Capital of the Company as on March. 31, 2026 was
of Rs. 3,00,00,00,000/- (Rupees Three Hundred Crores only) comprising of 30,00,00,000
(Thirty Crores) Equity Shares having face value of Rs. 10/- (Rupees Ten only) each.
During the financial year 2025-26, the Authorised Share Capital of the
Company was increased from Rs. 1,00,00,00,000 (Rupees One Hundred Crores only) to Rs.
3,00,00,00,000 (Rupees Three Hundred Crores only).
Further the Issued, Subscribed and Paid-up equity share capital of the
Company as on March. 31, 2026 was of Rs. 1,59,16,53,150 /- (Rupees One Hundred Fifty Nine
Crores Sixteen Lakhs Fifty Three Thousand One Hundred Fifty only) comprising of
15,91,65,315 (Fifteen Crores Ninety One Lakh Sixty Five Thousand Three Hundred Fifteen)
Equity Shares having face value of Rs. 10/- (Rupees Ten Only) each.
The summary of changes in Issued, Subscribed and paid-up Equity Share
Capital (Equity shares of face value of rupees ten each, fully paid-up) during the
financial year 2025-26, is as under:
| Particulars |
Number of shares |
Amount in J |
| Opening Balance as on April 01, 2025 |
5,29,93,451 |
52,99,34,510 |
| Addition on account of allotment of shares under Thyrocare
Employee Stock Option Scheme |
64,070 |
6,40,700 |
| Addition on account of allotment of Bonus Shares |
10,61,07,794 |
1,06,10,77,940 |
| Closing Balance as on March. 31, 2026 |
15,91,65,315 |
1,59,16,53,150 |
Bonus Issue
During the year under review, the Board of Directors, at its meeting
held on October 14, 2025, approved and recommended the issuance of Bonus Equity Shares in
the ratio of 2 (Two) new fully paid-up Equity Shares of RS. 10/- (Rupees Ten Only) each
for every 1 (One) existing Equity Share held by the shareholders as on the Record Date,
i.e., November 28, 2025 in the Company.
The aforesaid issue of Bonus Shares was approved by the shareholders
through Postal Ballot, the results of which were declared on November 16, 2025, being the
last date of e-voting for the Postal Ballot Notice dated October 14, 2025.
Pursuant to the aforesaid approval of shareholders, the Company
allotted 10,61,07,794 fully paid-up Bonus Equity Shares of RS. 10/- (Rupees Ten Only)
each.
Public Deposits
The Company has not accepted any deposits from the public/ members
during the year under review and accordingly no amount on account of principal or interest
on public deposits was outstanding as on March. 31, 2026.
DIRECTORS AND KEY MANAGERIAL PERSONNEL ("KMP")
The Board comprises distinguished professionals of proven integrity and
competence, who provide strategic direction, guidance and leadership to the Company.
a) Changes in Directors and KMP
During the financial year under review, in accordance with the
provisions of the Act and the rules made thereunder, the following changes occurred in the
constitution of the Board of Directors and Key Managerial Personnel (KMPs) of the Company:
1. Mr. Hardik Kishor Dedhia (DIN: 06660799) has stepped down from the
position of Directorship of the Company with effect from July 24, 2025.
2. Mr. Alok Kumar Jagnani has resigned from the position of Chief
Financial Officer and Key Managerial Personnel of the Company with effect from close of
business hours on July 23, 2025.
3. Mr. Alok Kumar Jagnani (DIN: 00644360) has been appointed as an
Additional Director in the Category of Non- Executive and Non-Independent Director of the
Company with effect from July 24, 2025 and subsequently his appointment was approved by
the Members of the Company through Postal Ballot on September 26, 2025, being last date of
e-voting for Postal Ballot.
4. Mr. Vikram Gupta was appointed as the Chief Financial Officer and
Key Managerial Personnel of the Company with effect from July 24, 2025.
Further, after the closure of FY 2025-26, following are the changes in
the Board of Directors and KMPs of the Company:
1. Mr. Dharmil Nirupam Sheth (DIN: 06999772) has stepped down from the
position of Directorship of the Company with effect from close of business hours of May
07, 2026.
2. Dr. Dhaval Rajesh Shah (DIN: 07485688) has stepped down from the
position of Directorship of the Company with effect from close of business hours of May
07, 2026.
3. The Board of Directors, at its meeting held on May 07, 2026,
considered and approved the following matters:
Appointment of Mr. Gaurav Verma (DIN: 11692586) as an Additional
Director in the category of Non-Executive Non-Independent
Director with effect from May 08, 2026, liable to retire by rotation.
Appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an
Additional Director in the category of Non-Executive Non-Independent Director with effect
from May 08, 2026, liable to retire by rotation.
Recommendation for the re-appointment of Mr. Rahul Franklin Guha
(DIN: 09588432) as the Chairman, Managing Director & Chief Executive Officer of the
Company for a further term of 5 (five) years from May 04, 2027 to May 03, 2032 (both days
inclusive), subject to the approval of the shareholders at the ensuing Annual General
Meeting of the Company. He shall not be liable to retire by rotation during the aforesaid
term.
b) Composition of Board of Directors and KMPs Board of Directors
As on March. 31, 2026, the Board of Directors of the Company comprised
of 9 (Nine) Directors, including 1 (one) Managing Director (Professional who is also an
Executive Chairman of the Board), 3 (three) Non-Executive & Non-Independent Directors,
and 5 (five) Non-Executive & Independent Directors (including two Independent Women
Directors) as detailed hereunder:
| Sr. Name of the Director No. |
DIN No. |
Designation |
| 1 Mr. Rahul Franklin Guha |
09588432 |
Chairman, Managing Director and Chief Executive Officer |
| 2 Mr. Dharmil Nirupam Sheth |
06999772 |
Non-Executive & Non-Independent Director |
| 3 Dr. Dhaval Rajesh Shah |
07485688 |
Non-Executive & Non-Independent Director |
| 4 Mr. Alok Kumar Jagnani@ |
00644360 |
Non-Executive & Non-Independent Director |
| 5 Dr. Indumati Gopinathan |
06779331 |
Non-Executive & Independent Director |
| 6 Dr. Prapti Ishwar Gilada |
07125024 |
Non-Executive & Independent Director |
| 7 Dr. Harshil Jiten Vora |
10232581 |
Non-Executive & Independent Director |
| 8 Mr. Nishant Amilal Shah |
09025935 |
Non-Executive & Independent Director |
| 9 Mr. Anandh Sundar |
10409065 |
Non-Executive & Independent Director |
The details of the Board and Committee positions, tenure of Directors,
areas of expertise and other details have been disclosed in the Corporate Governance
Report, which forms part of this report and is also available on the Company's website at https://investor. thyrocare.com/board-of-directors
The composition of the Board of Directors of the Company is in
accordance with Section 149(4) of the Act and Regulation 17 of the SEBI LODR Regulations.
In terms of the provisions of Sections 2(51) and 203 of the Act, the Company had all 3
(three) KMPs in place as on March. 31, 2026.
During financial year 2025-26, the Non-Executive Directors of the
Company had no pecuniary relationship or transactions with the Company other than sitting
fees and reimbursement of expenses, as applicable.
Declaration by Independent Directors
During the financial year under review, all the Independent Directors
of the Company have given their respective declaration(s) of independence in terms of
Section 149(6) & (7) of the Act and Regulation 16(1)
(b) of the SEBI LODR Regulations that he / she is not aware of any
circumstance or situation, which exists or may be reasonably anticipated, that could
impair or impact his / her ability to discharge his / her duties with an objective
independent judgment and without any external influence. The Independent Directors have
complied with the Code of Conduct prescribed in Schedule IV to the Act and the Company has
received affirmation for the same from all the Independent Directors. The Independent
Directors of the Company have enrolled themselves with the Indian Institute of Corporate
Affairs, in terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment
and Qualification of Directors) Rules, 2014.
The Board of Directors have taken on record declaration and
confirmation made by the Independent Directors. Further, the Board of Directors of the
Company has satisfied itself and is of the opinion that the Independent Director(s)
possess relevant expertise and experience (including the proficiency) and are persons of
integrity.
Based on the declaration received from the directors, none of the
directors are disqualified under Section 164(2) of the Act or are debarred by SEBI or any
other statutory authority from holding a position as director as of March. 31, 2026.
The Company undertakes various initiatives to familiarise the
Independent Directors with the Company, including its business model, strategic
plans, operations, industry dynamics, and regulatory environment.
The Independent Directors are periodically updated through
presentations at Board and Committee meetings on key aspects such as business performance,
operational developments, industry trends, risks and opportunities. Familiarisation
programmes are also conducted separately, as and when required, to enable Independent
Directors to gain deeper insights into the Company's functioning.
Details of familiarisation programmes imparted to Independent Directors
are disclosed on Company's website at
https://investor.thyrocare.com/wp-content/ uploads/2025/03/Familiarisation-Programme-for-
Independent-Directors.pdf
Key Managerial Personnel
As on March. 31, 2026, following are Key Managerial Personnel of the
Company in terms of the provisions of Sections 2(51) and 203 of the Act:
| Sr. Name No. |
Designation |
Date of change during the year, if applicable |
| 1 Mr. Rahul Franklin Guha |
Managing Director and Chief Executive Officer |
No change. |
| 2 Mr. Vikram Gupta |
Chief Financial Officer |
Appointed with effect from July 24, 2025 |
| 3 Mr. Brijesh Kumar |
Company Secretary & Compliance Officer |
No Change |
c) Directors Liable to retire by Rotation
Mr. Alok Kumar Jagnani (DIN 00644360) is liable to retire by rotation
at the ensuing Annual General Meeting (AGM) of the Company pursuant to the provisions of
Section 152 of the Act read with the Companies (Appointment and Qualification of
Directors) Rules, 2014 and the Articles of Association of the Company and being eligible,
he has offered himself for re-appointment, on the recommendation of the Nomination and
Remuneration Committee and the Board of Directors of the Company.
Particulars in pursuance of Regulation 36 of the SEBI LODR Regulations
read with Secretarial Standard - 2 on General Meetings relating to Mr. Alok Kumar Jagnani
(DIN 00644360) are included in the Notice of AGM.
d) Performance Evaluation
The Board adopted a formal mechanism for evaluating its performance, as
well as that of its Committees and individual Directors, including the Chairperson of the
Board.
The evaluation of the Board, Board Committees and Directors was carried
out in accordance with the provisions of the Act, SEBI LODR Regulations and Guidance Note
issued by SEBI in this regard. Questionnaires were circulated to all the directors
for their feedback on Board, Board Committees, Chairman of the Board
and other directors for evaluation. Meeting of the Independent Directors were held on July
31, 2025 and January 20, 2026, where they reviewed and discussed the feedback on the
functioning of the Board, Board Committees, Chairman and other directors including
Executive Directors. The Nomination and Remuneration Committee and Board of Directors, at
their meeting held on January 28, 2026, also reviewed the feedback on the evaluation of
the functioning of the Board, Board Committees, Chairman and other directors.
e) Number of meetings of the Board of Directors
The Board of Directors met 4 (four) times during financial year
2025-26. The details of the Board meetings and the attendance of Directors thereat are
provided in the Corporate Governance Report, which forms part of this Report.
f) Directors' Responsibility Statement
Pursuant to the provisions of Section 134(5) of the Act, and to the
best of their knowledge and belief, your Directors confirm that:
a) in the preparation of the annual accounts for the financial year
ended March. 31, 2026, the applicable accounting standards read with the
requirements set out under Schedule III to the Act, have been followed
and there are no material departures from the same;
b) the Directors have selected such accounting policies and applied
them consistently and made judgments and estimates that are reasonable and prudent so as
to give a true and fair view of the state of affairs of the Company as of March. 31, 2026,
and of the Profit of the Company for the year ended on that date;
(c) the Directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provisions of the Act
for safeguarding the assets of the Company and for preventing and detecting fraud and
other irregularities;
(d) the Directors have prepared the annual accounts on a going concern
basis;
(e) the Directors have laid down internal financial controls to be
followed by the Company and such internal financial controls are adequate and operating
effectively; and
(f) the Directors have devised proper systems to ensure compliance with
the provisions of all applicable laws and such systems were adequate and operating
effectively.
MANAGEMENT DISCUSSION AND ANALYSIS REPORT
As required under the provisions of Regulation 34(2) (e) of the SEBI
LODR Regulations, a separate section on Management Discussion and Analysis Report
outlining the business of your Company is annexed to this Report.
AUDITORS AND AUDITORS' REPORT
a) Statutory Auditors and Auditors' Report
The Members of the Company, at their 21st Annual General Meeting
("AGM") held on June 26, 2021, had approved the appointment of M/s. M S K A
& Associates LLP, Chartered Accountants, (Firm's Registration No. 105047W), as the
Statutory Auditors of the Company for a period of 5 (five) years from the conclusion of
the said AGM until the conclusion of 26th AGM of the Company to be held in the year 2026.
Accordingly, M/s. M S K A & Associates LLP, will complete their present term on
conclusion of 26th AGM in terms of the said approval and Section 139 of the Act read with
the Companies (Audit and Auditors) Rules, 2014.
The Statutory Auditors of the Company have issued Audit Reports on the
Standalone and Consolidated Annual Financial Statements of the Company with unmodified
opinion. The reports of Statutory Auditors on Standalone and Consolidated Financial
Statements forms part of the Annual Report. There are no qualifications, reservations,
adverse remarks, disclaimer or emphasis of matter in the Auditors' Reports.
Further the Statutory Auditors of the Company have not reported any
matter under Section 143(12) of the Act.
The Board of Directors of the Company ("the Board"), on the
recommendation of the Audit Committee ("the Committee"), have recommended, for
the approval of the shareholders, the appointment of M/s. Price Waterhouse Chartered
Accountants LLP (Firm Registration No. 012754N/N500016) as the Statutory Auditors of the
Company for a period of 5 (five) years commencing from the conclusion of the ensuing AGM
till the conclusion of the 31st AGM of the Company to be held in the year 2031.
A resolution in this regard for seeking approval of the Shareholders
forms part of the Notice of the ensuing AGM.
b) Secretarial Auditors and Secretarial Audit Report
Pursuant to the provisions of Section 204 of the Act and Regulation 24A
of SEBI LODR Regulations, the Shareholders of the Company have appointed M/s. Mehta &
Mehta, Company Secretaries (Firm Registration No.: MU000019250), to conduct the
Secretarial Audit of the Company from financial year 2025-26 to financial year 2029-30.
The Secretarial Audit Report for the financial year 2025-26, issued by
M/s Mehta & Mehta, Company Secretaries, in Form MR-3 is annexed as Annexure 1 to this
Report. The report of Secretarial Auditors does not contain any qualification,
reservation, adverse remark or disclaimer.
Further, as per the requirement of Regulation 24A of SEBI LODR
Regulations, the Secretarial Audit Report for the financial year 2025-26 of the material
subsidiary of the Company namely Nueclear Healthcare Limited is also attached as Annexure
2 to this Report.
Further, the Secretarial Auditors of the Company have not reported any
matter under Section 143(12) of the Act in their report for FY 2025-26.
c) Cost Records and Cost Auditors
The cost accounts and records as required to be maintained under
Section 148 (1) of the Act are duly made and maintained by the Company.
Mr. S. Thangavelu, Cost and Management Accountant, was appointed as a
Cost Auditor to audit the cost records for the financial year 2025-26. The Shareholders,
at the 25th AGM, had ratified the remuneration of RS. 1,10,000/- payable to Mr. S.
Thangavelu, Cost Auditor of the Company, for the financial year ended March. 31, 2026.
The cost audit report for FY 2024-25 submitted by the said Cost Auditor
during the FY 2025-26 does not contain any qualification, reservation or adverse remark.
Further, the Cost Auditor of the Company has not reported any matter under Section 143(12)
of the Act in their report for FY 2024-25.
Further, the Board of Directors of the Company, upon recommendation of
the Audit Committee have appointed M/s. Jitender Navneet & Co., Cost Accountants (Firm
Registration No. 000119), as the Cost Auditor to audit the cost records for the financial
year 2026-27. M/s. Jitender Navneet & Co., Cost Accountants, has given their consent
for being appointed as the Cost Auditor of the Company for the financial year 2026-27. The
remuneration payable to the Cost Auditor is subject to ratification by the Shareholders of
the Company. Accordingly, a resolution seeking Shareholders' ratification for the
remuneration payable to M/s. Jitender Navneet & Co., Cost Accountants is included in
the Notice to the ensuing AGM along with relevant details, including the proposed
remuneration.
d) Internal Auditors
M/s. Ernst & Young, Chartered Accountants, Internal Auditors of the
Company, conducted the Internal Audit for the financial year 2025-26 as per the provisions
of Section 138 of the Act read with Rule 13 of the Companies (Accounts) Rules, 2014. Their
reports were reviewed by the Audit Committee and Risk Management Committee and follow-up
measures were taken by the relevant teams and committees of the Board, wherever necessary.
e) Reporting of Frauds, if any, by Auditors
During the year under review, none of the Auditors have reported any
instance of fraud committed against the Company by its officers or employees, details of
which need to be mentioned under the provisions of sub-section (12) of
section 143 of the Act.
COMMITTEES OF THE BOARD
The Board of Directors of your Company has formed various Committees to
effectively discharge its functions and responsibilities in compliance with the
requirements of applicable laws and as a part of the best corporate governance practices.
The terms of reference and the constitution of those Committees are in compliance with the
applicable laws.
The Committees of the Board are as under:
a) Audit Committee;
b) Nomination and Remuneration Committee;
c) Stakeholders Relationship Committee;
d) Corporate Social Responsibility Committee;
e) Risk Management Committee
The details with respect to the composition, roles, terms of reference,
etc. of the aforesaid committees are given in detail in the "Corporate Governance
Report" which forms part of this Report. The dates on which meetings of Board
Committees were held during the financial year under review, along with the number of
meetings attended by the respective Committee members, are also disclosed in the
"Corporate Governance Report". The minutes of the Meetings of all Committees are
circulated to the Board for its noting. During the year, all recommendations of the
Committees of the Board were accepted by the Board.
SUBSIDIARIES,ASSOCIATES AND JOINT VENTURES
I Subsidiary Companies:
As on March. 31, 2026, the Company has 4 (Four) Subsidiaries:
a) Nueclear Healthcare Limited ("NHL")
Nueclear Healthcare Limited is a leading PET-CT imaging network in
India, operating across major cities including Mumbai, Delhi, Hyderabad, and Bengaluru.
Established in 2011, NHL uses advanced PET-CT and CT technologies for accurate cancer
diagnosis, staging, and monitoring. Licensed by the Atomic Energy Regulatory Board, NHL
also operates medical cyclotrons to produce essential radioactive biomarkers like FDG,
PSMA, and DOPA. Committed to patient care, NHL upholds the highest quality standards in
cancer imaging.
In financial year 2025-26, NHL achieved revenue of RS. 44.62 crores,
Operating EBITDA of RS. 6.16 crores and PAT of RS. 6.16 crores.
b) Think Health Diagnostics Private Limited ("Think Health")
Think Health is a diagnostic and preventive healthcare service provider
specializing in at- home electrocardiogram (ECG) services.
In financial year 2025-26, Think Health recorded a revenue of RS. 0.01
crores, an operating EBITDA of RS. 0.05 crores and a PAT of RS. 0.21 crores.
c) Pulse Hitech Health Services (Ghatkopar) LLP ("Pulse LLP")
Pulse LLP is involved in the business of rendering of various services
relating to CT Scan, MRI, diagnosis and other health services.
In financial year 2025-26, Pulse Hitech recorded a revenue of RS. 8.52
crores, an operating EBITDA of RS. 2.41 crores and a PAT of H (0.39) crores.
d) Thyrocare Laboratories (Tanzania) Limited ("Thyrocare
Tanzania")
Thyrocare Tanzania operates in the diagnostic and healthcare services
sector and was initially established as a joint venture between the Company and the
Kastipharm Group, comprising Kastipharm Limited, Mr. Anwar Alnoor Kachra, and Mr. Joseph
Philemon Mgaya. With effect from April 01, 2025, Thyrocare Tanzania ceased to be a Joint
Venture Company and became a Subsidiary Company pursuant to acquisition of more than
majority stake in the Company on June 03, 2025.
In financial year 2025-26, Thyrocare Tanzania reported a revenue of RS.
2.73 crores, an operating EBITDA of H (3.02) crores and a PAT of H (4.53) crores.
II Associate Company:
Equinox Labs Private Limited ("Equinox Labs")
Equinox Labs is India's Leading expert in Food, Water, Air Testing and
Food Safety Audits. Equinox is an FSSAI Notified and NABL Accredited Lab with Clients
Across India.
In financial year 2025-26, Equinox Labs recorded a revenue of RS. 43.25
crores, an operating EBITDA of RS. 8.82 crores and a PAT of RS. 4.47 crores.
During the year under review, the Board of Directors have reviewed the
affairs of the subsidiaries. Pursuant to the provisions of Section 129(3) of the Act, a
statement containing salient features of the financial statements of the Company's
Subsidiaries and Associate Company is given in Form AOC 1 attached herewith as Annexure 3
to this Report.
The Company has formulated a Policy for determining material
subsidiaries and its governance. The said Policy is available on the website of the
Company at
https://investor. thyrocare.com/wp-content/uploads/2024/07/1-Policy-on-
Material-Subsidiary.pdf
Further, pursuant to the provisions of Section 136 of the Act, the
financial statements of the Company, consolidated financial statements along with relevant
documents, and separate audited financial statements in respect of subsidiaries are
available on the Company's website at https:// investor.thvrocare.com/financials/subsidiarv-financials/
During the year, your Company has made investment in Thyrocare Tanzania
through total equity infusion of USD 6,00,000.
POLICIES, FRAMEWORK AND CONTROLS
a) Risk Management Framework and Policy
The Board of Directors of the Company has in place a Risk Management
Policy to ensure sustainable business growth with stability and to promote a proactive
approach in identifying, reporting, evaluating and resolving various risks associated with
the business. The main objective of the Risk Management Policy of the Company is to
establish a pro-active approach in foreseeing, evaluating, controlling, mitigating and
resolving all kinds of risks associated with the business, so as to ensure sustainable
business growth with stability. Your Company's SOPs, organizational structure, management
systems, code of conduct, policies and values together govern how your Company conducts
its business and manages associated risks.
The Risk Management Policy enables the management to understand the
risk environment and assess the specific risks and potential exposure to your Company,
determine how to deal best with these risks to manage overall potential exposure, monitor
and seek assurance of the effectiveness of the management of these risks and intervene for
improvement where necessary and report throughout the management chain up to the Risk
Management Committee about how risks are being monitored, managed, assured and
improvements are made.
During the year under review, the Committee reassessed its enterprise
level risks and related mitigation plan. Risk management is an ongoing activity
considering the dynamic business environment in which Company operates. Continuous
re-assessment of risks and mitigation plan has helped the Company to mitigate new evolving
risks and minimise adverse effect of such risk in the interest and for the benefit of all
the stakeholders.
The Risk Management Policy of the Company can be accessed on website of
the Company at
https:// investor.thyrocare.com/wp-content/uploads/2024/04/
Risk-Management-Policy-TTL.pdf .
b) Vigil Mechanism (Whistle Blower Policy)
In accordance with the provisions of Section 177(9) and (10) of the Act
and Regulation 22 of the SEBI LODR Regulations, the Company has established a robust Vigil
Mechanism (Whistle Blower Policy). The Company is deeply committed to maintaining the
highest standards of ethical, moral, and legal business conduct and strives to provide a
respectful and transparent work environment for its employees as well as external
stakeholders.
The Vigil Mechanism enables directors, employees, and other
stakeholders, including vendors and partners, to report concerns relating to unethical
behaviour, actual or suspected fraud, or violations of the Company's Code of Conduct. The
mechanism provides for adequate safeguards against victimization of persons who use such
mechanism and makes provision for direct access to the Chairperson of the Audit Committee
in appropriate cases.
The Whistle Blower Policy of the Company can be accessed on website of
the Company athttps://investor.
thyrocare.com/wp-content/uploads/2024/07/3-
Whistleblower-Policv_Thyrocare.pdf
During the financial year 2025-26, the Company has not received any
whistle blower complaint.
c) Nomination and Remuneration Policy
The Company has implemented the Nomination and Remuneration Policy,
which includes the criteria for determining qualifications, positive attributes,
independence of directors, and other relevant matters, in accordance with the provisions
of sub-section (3) of Section 178 of the Act, and Regulation 19 read with Part D of
Schedule II of the SEBI LODR Regulations. The salient features of the Policy and other
related details are disclosed in the Corporate Governance Report annexed to this Report.
The Policy is also available on the Company's website at
https://investor.thyrocare. com/wp-content/uploads/2025/03/Nomination-and-
Remuneration-Policy.pdf
d) Internal Financial Controls
Internal Financial Controls are an integrated part of the risk
management process, addressing financial risks and financial reporting risks. The Board
has adopted policies and procedures for ensuring the orderly and efficient conduct of its
business, including adherence to the Company's policies, the safeguarding of its assets,
the prevention and detection of frauds and errors, the accuracy and completeness of the
accounting records, and the timely preparation of reliable financial disclosures.
Assurance on the effectiveness of internal financial controls is
obtained through management reviews, continuous monitoring by functional experts and
testing of the internal financial control systems by the Internal Auditors during the
course of their audits. We believe that these systems provide reasonable assurance that
our internal financial controls are designed effectively considering the nature of our
industry and are operating as intended. During the year, such controls were tested and no
reportable material weakness in the design or operation of such systems was observed.
DISCLOSURES
a) Particulars of contracts or arrangements with related parties
All the arrangements or transactions entered by the Company during the
financial year with related parties were on an arm's length basis and in the ordinary
course of business. All related party transactions are placed for approval before the
Audit Committee and also before the Board wherever necessary in compliance with the
provisions of the Act and SEBI LODR Regulations.
During the financial year 2025-26, the Company entered into material
related party transactions only with its Holding Company, Docon Technologies Private
Limited ("Docon"), for which prior approval of the shareholders had already been
obtained at the 25th Annual General Meeting. The disclosure of material related party
transactions as required under section 134 of the Act in form AOC-2 are set out in
Annexure 4 of this report.
Details of the related party transactions form part of the standalone
financial statements.
Pursuant to the SEBI LODR Regulations, the resolution for seeking
approval of the Shareholders on material related party transactions to be entered in the
FY 202627 is being placed at this AGM.
Pursuant to the requirements of the Act and the SEBI LODR Regulations,
the Company has formulated a Policy on Related Party Transactions and is available on
Company's website URL at:
https://investor. thyrocare.com/wp-content/uploads/2026/01/RPT-
Policy_28.01.2026.pdf
b) Particulars of loans given, investments made, guarantees given, and
securities provided
In accordance with Section 186 of the Act, the Company has made total
investment of USD 6,00,000 by way of subscription of Compulsorily Convertible Preference
Shares in Thyrocare Tanzania.
Further, during the financial year 2025-26, the Company has not granted
any loans, guarantees, or securities in connection with any loan to its subsidiaries,
joint ventures, associate companies, or any other body corporates or persons.
c) Corporate Social Responsibility
The brief outline of the Corporate Social Responsibility
("CSR") Policy of the Company and the initiatives undertaken by the Company on
CSR activities during the year in the format prescribed in the Companies ('CSR Policy')
Rules, 2014 are set out in Annexure 5 of this Report. The CSR Policy is available on
Company's website at URL:
https://investor.thyrocare. com/wp-content/uploads/2026/01/Corporate-Social-
Responsibilitv-Policv_28.01.2026.pdf
Your Company has formed the Corporate Social Responsibility
("CSR") Committee as per the requirement of the Act. The details of composition
of CSR Committee are covered in the "Corporate Governance Report" which forms
part of this Report.
The entire amount earmarked for CSR expenditure during the year under
review has been fully contributed and effectively utilized towards CSR initiatives.
d) Particulars of employees
Disclosures concerning the remuneration of Directors and KMPs as per
Section 197(12) of the Act, read with Rule 5(1) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014 is given in Annexure 6 to this Report.
Your Directors affirm that the remuneration paid to Directors and KMPs is as per the
Nomination and Remuneration Policy of the Company.
In accordance with the provisions of Section 197(12) of the Act, and
Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules,
2014, the names and other particulars of employees are available with the Company. In
terms of provisions of Section 136(1) of the Act, any member intends to obtain a copy of
the said details may write to the Company Secretary and Compliance Officer of the Company
at compliance@thyrocare.com.
None of the employees listed in the said Annexure are related to any
Director of the Company.
e) Employees Stock Purchase / Option Schemes
The shareholders of the Company had approved the Thyrocare Employees
Stock Option Scheme ("ESOS/ Scheme") in the Annual General Meeting
("AGM") held on September 08, 2014, September 26, 2015, which was subsequently
modified in the AGM held on August 10, 2023. Pursuant to the said modification, the
shareholders authorized the Board of Directors and/or the Nomination and Remuneration
Committee to grant stock options to eligible employees until all remaining options under
the ESOS are exhausted and the equivalent number of equity shares have been issued and
allotted. Further, the Shareholders of the Company have approved extension of ESOS to
eligible employees of the Holding and/or Subsidiary Company(ies) of
Thyrocare by way of a Special Resolution passed through postal ballot
(Notice dated October 23, 2024) on January 09, 2025.
The Scheme is in compliance with the Securities and Exchange Board of
India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ('SEBI (SBEB)
Regulations') and other applicable laws. The Scheme is available on the website of the
Company at
https://investor.thyrocare.com/wp-content/ uploads/2025/03/Revised_TTL_ESOP-Scheme.pdf
The disclosures required to be made under Regulation 14 of the SEBI
(SBEB) Regulations relating to Employees Stock Option Scheme is available on the website
of the Company at
https://investor. thyrocare.com/wp-content/uploads/2026/06/ESOP-
Disclosure-2025-26.pdf
During the financial year 2025-26, the Company granted 1,00,150 stock
options to eligible employees of the Company and/or its subsidiary company. Further, the
Company allotted 64,070 equity shares having face value of Rs.10/- (Rupees Ten Only) each
to eligible employees pursuant to the exercise of options under the Scheme.
f) Human Resources
Please refer to the paragraphs on Human Resources in the Management
Discussion & Analysis section for detailed analysis.
g) Report under Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act 2013.
The Company, as a responsible employer, is committed to maintaining a
workplace that is free from all forms of sexual harassment.
It has adopted a Policy on the Prevention of Sexual Harassment at the
workplace and has duly constituted an Internal Complaints Committee in accordance with the
provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and
Redressal) Act, 2013. The Company also regularly conducts training and awareness sessions
for its employees to promote a safe, respectful, and inclusive work environment.
Details required under the Sexual Harassment of Women at Workplace
(Prevention, Prohibition and Redressal) Act, 2013, is provided below:
| Particulars No. |
Details |
| a. Number of complaints of sexual harassment received in the
year |
Nil |
| b. Number of complaints disposed of during the year |
Nil |
| c. Number of cases pending for more than ninety days |
Nil |
h) Conservation of energy, technology absorption and foreign exchange
earnings and outgo:
Pursuant to the provisions of Clause (m) of SubSection 3 of Section 134
of the Act, read with Rule 8 (3) of the Companies (Accounts) Rules 2014, the details of
conservation of energy, technology absorption, foreign exchange earnings and outgo, are
given out in Annexure 7 to this report.
i) Corporate Governance Report
The Report on Corporate Governance, as stipulated under Regulation 34
of the SEBI LODR Regulations is annexed to this Report. The Corporate Governance Report
also contains certain disclosures required under the Act for the financial year under
review.
A certificate from M/s. Mehta & Mehta, Secretarial Auditors of the
Company, regarding compliance with the conditions of Corporate Governance as stipulated in
Part C of Schedule V of the SEBI LODR Regulations, is annexed to the Corporate Governance
Report.
j) Business Responsibility and Sustainability Report
As required under the Regulation of 34 (2) (f) of the SEBI LODR
Regulations, a separate section on Business Responsibility and Sustainability Report
("BRSR"), describing the initiatives taken by the Company from an Environmental,
Social and Governance perspective, is annexed to this Report.
k) Compliance with Secretarial Standards
The Company has devised proper systems to ensure compliance with the
provisions of Secretarial Standards on Meetings of the Board of Directors (SS-1) and
General Meetings (SS-2) issued by the Institute of Company Secretaries of India and that
such systems are adequate and operating effectively.
l) Annual Return
Pursuant to the provisions of Section 92(3) read with Section 134(3)(a)
of the Act, the annual return is available under the 'Investors' section of the Company's
website and can be viewed at the following link:
https:// investor.thvrocare.com/wp-content/uploads/2026/06/
MGT-7_Thyrocare_AC3499635.pdf
m) Material changes and commitments, if any, affecting the financial
position of the Company which have occurred between the end of the financial year of the
Company to which the financial statements relate and the date of the report.
There are no material changes affecting the financial position of the
Company, subsequent to the close of the financial year 2025-26 till the date of this
Report.
n) Transfer of unpaid/ unclaimed dividend amount and shares to Investor
Education & Protection Fund ("IEPF").
Pursuant to the applicable provisions of the Act, read with the IEPF
Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the IEPF
Rules"), all unpaid or unclaimed dividends are required to be transferred by the
Company to the IEPF, established by the Government of India, after the completion of seven
years. Further, according to the IEPF Rules, the shares on which dividend has not been
paid or claimed by the shareholders for seven consecutive years or more shall also be
transferred to the demat account of the IEPF Authority.
During the year, the Company has transferred the unclaimed and unpaid
dividends and corresponding shares on which dividends were unclaimed for seven consecutive
years were transferred to the IEPF Authority as per the requirements of the IEPF Rules as
detailed below:
| Type of Dividend |
Amount of unclaimed dividend transferred |
Number of corresponding equity shares
transferred |
| Final Dividend for the FY 2017-18 |
Rs. 55,740 |
154 |
Year-wise amounts of unpaid/unclaimed dividends lying in the unpaid
account up to the year, which are liable to be transferred have been provided in the
Corporate Governance Report and are also available on the website of the Company at https://investor. thyrocare.com/unclaimed-dividend/
o) Details of Shares in Demat / Unclaimed Suspense Account
The Company does not have any shares in the Demat suspense account or
unclaimed suspense account.
p) Disclosures pursuant to Clause 5A, Para A, Part A of Schedule III of
SEBI LODR Regulations
API Holdings Limited ("API"), the ultimate holding company of
the Company, has raised debt through the issuance of secured, unlisted, redeemable,
nonconvertible debentures aggregating up to INR 1,700 crores ("Debentures").
In connection with the aforesaid issuance, Docon Technologies Private
Limited, a promoter entity of the Company, has created a pledge over 9,69,69,696 equity
shares of the Company, in favour of Catalyst
Trusteeship Limited, acting as the Debenture Trustee, to secure API's
obligations under the Debentures.
In relation to the aforesaid Debentures, certain agreements have been
executed by the promoter entities of the Company, to which the Company is not a party,
inter alia, for the creation of encumbrance over the shares of the Company.
The aforesaid creation of encumbrance over the equity shares of the
Company has been duly disclosed to the stock exchanges in compliance with applicable
regulations.
Brief details of the aforesaid agreements are available on the
Company's website at:
https://investor.thyrocare. com/wp-content/uploads/2025/09/Disclosure-under-
Regulation-30A-of-LODR.pdf
q) Change in the nature of business:
There is no change in the nature of business of the Company during the
year under review.
r) Details of significant and material orders passed by the regulators
or courts or tribunals impacting the going concern status and the Company's operations in
future:
No significant and material order has been passed by the regulators,
courts, or tribunals impacting the going concern status and Company's operations in
future.
s) The Code on Social Security, 2020 - Maternity benefit
The Company is in compliance with the applicable provisions relating to
maternity benefits as prescribed under the Maternity Benefit Act, 1961/ the Code on Social
Security, 2020.
t) Other Disclosures
Your Directors state that no disclosure or reporting
is required in respect of the following matters as
there were no transactions on these items during the
year under review:
No application has been made, and no proceeding is pending under
the provisions of Insolvency and Bankruptcy Code, 2016 during the year against the
Company.
The Company has not made any one
time settlement with any of the bank or financial institution.
The Company has not issued any equity
shares with differential rights as to dividend, voting or otherwise.
The Company has not issued any sweat equity shares.
The Company has not raised any funds
through preferential allotment or qualified institutional placement.
The Managing Director of the Company has not received any
remuneration or commission from any of its subsidiaries.
Acknowledgements
The Directors wish to convey their appreciation to all the employees of
the Company for their contribution towards the Company's performance. The Directors would
also like to thank the members, customers, dealers, suppliers, bankers, governments and
all other business associates for their continuous support to the Company and their
confidence in its management.
|